Thursday, 15 October 2026European Markets

ELKEM Stock Is 12% Down So Far Today

Loading stream...

(VIANEWS) - Shares of ELKEM (Oslo Børs Benchmark Index_GI: ELK.OL) dropped by a staggering 12.68% to kr22.44 at 14:23 EST on Friday, after four successive sessions in a row of gains. Oslo Børs Benchmark Index_GI is dropping 0.77% to kr1,204.23, following the last session's downward trend. This seems, as yet, a somewhat down trend exchanging session today.

About ELKEM

Elkem ASA provides silicones, silicon products, and carbon solutions worldwide. The company offers silicones polymers, including chlorosilanes and silicone oils; silicone elastomers, comprising liquid silicone rubber, heat cured rubber, and RTV-1 and RTV-2 silicones; and silicone fluids, such as silicone resin, silicone compounds, silicone grease, and silicone emulsion. It also provides silicon based materials comprising silicon, silicon powder/micronized silicon, silica fume/ microsilica, ferrosilicon, grain refiner, silicon and boron carbide, ferrosilicon nitride, fused silica, polymer additives, and specialties for refractories. In addition, the company offers foundry alloys, such as foundry alloys, preconditioners, recarburizers, conditioners, nodularizers, inserts, and inoculants; and carbon based materials comprising furnace tapping materials, cathode ramming paste, furnace lining materials, electrode paste, and prebaked and other electrodes. The company was founded in 1904 and is headquartered in Oslo, Norway. Elkem ASA is a subsidiary of Bluestar Elkem International Co., Ltd. S.A.

Earnings Per Share

As for profitability, ELKEM has a trailing twelve months EPS of kr12.35.

PE Ratio

ELKEM has a trailing twelve months price to earnings ratio of 1.82. Meaning, the purchaser of the share is investing kr1.82 for every norwegian krone of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ELKEM's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for ELKEM is 3837860 which is 298.54% above its average volume of 962959.

Volatility

ELKEM's last week, last month's, and last quarter's current intraday variation average was a positive 0.74%, a negative 0.40%, and a positive 1.63%.

ELKEM's highest amplitude of average volatility was 0.74% (last week), 1.30% (last month), and 1.63% (last quarter).

More news about ELKEM (ELK.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com